Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Residual Invasive Breast Cancer”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Not applicableUnknownNCT05754502
What this trial is testing

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Who this might be right for
Breast Cancer
Consorzio Oncotech 300
Not applicableLooking for participantsNCT05196087
What this trial is testing

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Who this might be right for
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto 500
Large-scale testing (Phase 3)Active Not RecruitingNCT05629585
What this trial is testing

Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Who this might be right for
Breast Cancer
AstraZeneca 1,174
Testing effectiveness (Phase 2)Looking for participantsNCT07191717
What this trial is testing

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Jonsson Comprehensive Cancer Center 42
Large-scale testing (Phase 3)Active Not RecruitingNCT04457596
What this trial is testing

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast Carcinoma+4 more
Alliance for Clinical Trials in Oncology 1,056
Large-scale testing (Phase 3)Active Not RecruitingNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,615
Testing effectiveness (Phase 2)Looking for participantsNCT04437160
What this trial is testing

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Triple Negative Breast Cancer
Chinese Academy of Medical Sciences 286
Not applicableUnknownNCT03821454
What this trial is testing

Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Active Not RecruitingNCT04622319
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Who this might be right for
HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
Daiichi Sankyo 1,600
Early research (Phase 1)Study completedNCT03473639
What this trial is testing

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Who this might be right for
Metastatic Breast CancerBreast Cancer
University of Virginia 13
Large-scale testing (Phase 3)Looking for participantsNCT06830889
What this trial is testing

BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 1,450
Large-scale testing (Phase 3)Looking for participantsNCT07679360
What this trial is testing

Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1,000
Not applicableWithdrawnNCT00914043
What this trial is testing

Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45

Who this might be right for
Breast CancerFatigue
NSABP Foundation Inc
Large-scale testing (Phase 3)Looking for participantsNCT05633654
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Who this might be right for
Triple Negative Breast Cancer
Gilead Sciences 1,514
Large-scale testing (Phase 3)Active Not RecruitingNCT02954874
What this trial is testing

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Who this might be right for
Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more
National Cancer Institute (NCI) 1,195
Not applicableUnknownNCT05951699
What this trial is testing

Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy

Who this might be right for
Breast Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 105
Testing effectiveness (Phase 2)Active Not RecruitingNCT03756298
What this trial is testing

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
National Cancer Center, Korea 284
Large-scale testing (Phase 3)Looking for participantsNCT04254263
What this trial is testing

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Who this might be right for
Locally Advanced Breast Cancer
RenJi Hospital 316
Not applicableLooking for participantsNCT05059444
What this trial is testing

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Who this might be right for
Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more
Guardant Health, Inc. 2,285
Large-scale testing (Phase 3)Active Not RecruitingNCT02445391
What this trial is testing

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast Carcinoma+9 more
ECOG-ACRIN Cancer Research Group 415
Next Page